Hideaki Mizutani
- Cancer Research top 10%
- Cancer Genomics and Diagnostics 3
-
- Cancer Immunotherapy and Biomarkers 9
- Lung Cancer Research Studies 8
- Colorectal Cancer Treatments and Studies 3
-
- Lung Cancer Treatments and Mutations 12
-
- Nausea and vomiting management 4
-
- Chemotherapy-induced organ toxicity mitigation 3
-
- Neuroendocrine Tumor Research Advances 2
Hideaki Mizutani
24 papers receiving 567 citations
Peers
Comparison fields: 5 of 67
- Cancer Research 225
- Oncology 166
- Pulmonary and Respiratory Medicine 144
- Molecular Biology 291
- Surgery 123
Countries citing papers authored by Hideaki Mizutani
This map shows the geographic impact of Hideaki Mizutani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideaki Mizutani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideaki Mizutani more than expected).
Fields of papers citing papers by Hideaki Mizutani
This network shows the impact of papers produced by Hideaki Mizutani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideaki Mizutani. The network helps show where Hideaki Mizutani may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hideaki Mizutani, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 6 | |
| 2 | 2024 | 9 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 11 | |
| 5 | 2023 | 4 | |
| 6 | 2023 | 4 | |
| 7 | 2022 | 6 | |
| 8 | 2021 | 5 | |
| 9 | 2020 | 12 | |
| 10 | 2019 | 114 | |
| 11 | 2019 | 3 | |
| 12 | 2019 | 3 | |
| 13 | 2017 | 13 | |
| 14 | 2016 | 5 | |
| 15 | 2013 | 161 | |
| 16 | 2012 | 153 | |
| 17 | Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer. | 2012 | 5 |
| 18 | 2010 | 27 | |
| 19 | 2009 | 1 | |
| 20 | 2009 | 2 |
About Hideaki Mizutani
Hideaki Mizutani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 25 papers that have together received 579 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Research Studies (8 papers), Nausea and vomiting management (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Cancer Genomics and Diagnostics (3 papers), Chemotherapy-induced organ toxicity mitigation (3 papers) and Neuroendocrine Tumor Research Advances (2 papers). The work is most often cited by research in Cancer Research (225 citations), Oncology (166 citations) and Pulmonary and Respiratory Medicine (144 citations). Hideaki Mizutani has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Masahiro Seike, Rintaro Noro, Akihiko Gemma, Yuji Minegishi, Kazuhiro Kitamura, Tetsuya Okano, Kuniko Matsuda, Akinobu Yoshimura, Chie Soeno and Akihiko Miyanaga. Their work appears in journals such as Journal of Clinical Oncology, Scientific Reports and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.